Lannett Co. has received approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for oxycodone hydrochloride (5 mg) capsules. an opioid painkiller.


Lannett, oxycodone hydrochloride capsules, Arthur Bedrosian, opioid painkiller, Lehigh Valley Technologies






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Lannett set to release oxycodone capsules

August 4th, 2014

PHILADELPHIA – Lannett Co. has received approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for oxycodone hydrochloride (5 mg) capsules. an opioid painkiller.

Lannett said Monday that its product is a therapeutic equivalent to the reference listed drug, oxycodone hydrochloride capsules (5 mg) of Lehigh Valley Technologies Inc.

The company expects to begin shipping the product in the coming months.

For the year ended in June, total sales of oxycodone hydrochloride capsules (5 mg) at average wholesale price were approximately $7.1 million, according to IMS Health data cited by Lannett.

"Oxycodone hydrochloride capsules (5 mg) represents our third product approved by the FDA thus far in 2014 and, importantly, adds to our goal of vertical integration," stated Arthur Bedrosian, president and chief executive officer of Lannett. "We hope to receive additional product approvals in the near future while we continue to develop our robust pipeline."

More Supplier News Breaks >>
Advertisement